ePoster

KINE-PD-28, AN ULTRA-SHORT PEPTIDE, RESCUES COGNITIVE AND SYNAPTIC DEFICITS THROUGH MICROGLIAL IMMUNE ACTIVATION AND ATTENUATION OF AMYLOID PATHOLOGY AND NEUROINFLAMMATION

Hye-Lim Chaand 3 co-authors

Kine Sciences

FENS Forum 2026 (2026)
Barcelona, Spain
Board PS03-08AM-129

Presentation

Date TBA

Board: PS03-08AM-129

Poster preview

KINE-PD-28, AN ULTRA-SHORT PEPTIDE, RESCUES COGNITIVE AND SYNAPTIC DEFICITS THROUGH MICROGLIAL IMMUNE ACTIVATION AND ATTENUATION OF AMYLOID PATHOLOGY AND NEUROINFLAMMATION poster preview

Event Information

Poster Board

PS03-08AM-129

Abstract

Alzheimer’s disease (AD) is the most prevalent form of dementia, characterized by the pathological accumulation of amyloid-beta (Aβ) and hyperphosphorylated tau proteins. Despite decades of research, effective disease-modifying therapies (DMTs) remain limited due to the heterogenetic etiology and complex interplay between molecular pathology and immune dysregulation.
We present KINE-PD-28, a novel nonameric peptide that modulates microglial immunity, as a promising therapeutic candidate for AD. KINE-PD-28 suppresses disease-associated microglia (DAM, or M1-like) that are causing notorious neuroinflammation in AD and promotes anti-inflammatory (M2-like) microglial phenotypes. In the meantime, KINE-PD-28 reduced pathological Aβ accumulation through enhancing the phagocytic function of microglia. Consequently, we found that KINE-PD-28 improved the synaptic dysfunction in the hippocampus and mitigated cognitive impairment in 5xFAD mice at 6 months of age.
Collectively, our findings endorse KINE-PD-28 as a first-in-class peptide-based DMT candidate that modulates microglial multifunctional immunity in AD, thereby ameliorating cognitive impairment. KINE-PD-28 is poised to fulfill critical unmet needs in current AD therapy.

Recommended posters

THE PM20D1-OLE PATHWAY INDUCES MICROGLIA REWIRING TO AMELIORATE ALZHEIMER DISEASE

Victoria Pozzi-Ruiz, Aida Giner de Gracia, Liliane Glauser, Mario Romani, Fatima Gunter-Rahman, Alejandro González-Ramón, Mahmood Haj-Yahya, Rajasekhar Kolla, Allison M Burns, Hilal A Lashuel, Johan Auwerx, Johannes Gräff, Jose V Sanchez-Mut

MICROGLIAL ADP RECEPTORS IN ALZHEIMER’S DISEASE: THERAPEUTIC POTENTIAL AND IMPLICATIONS

Uxía Fraga-Bouzas, Yixia Jin, Irene Pallás, Carlos Alberto Saura, Mar Puigdellívol

EFFECTS OF THE MULTIFACTORIAL CHRONOKINE HEBE2 IN HUMAN IPSC-DERIVED NEURAL CELLS MODELING ALZHEIMER'S DISEASE

David Ramirez Gomez, Alejandro Brao, Jon Esandi, Oscar Conchillo-Solé, Xavier Daura, Assumpció Bosch, Joan Roig-Soriano, Miguel Chillón, Bea Almolda

DYRK1A INHIBITION WITH THE NOVEL THERAPEUTIC, DYR533, IN THE PS19 MOUSE MODEL OF TAUOPATHY ATTENUATES TAU PATHOLOGY, NEUROINFLAMMATION, AND SYNAPTIC FUNCTION

Samantha Bartholomew, Wendy Winslow, Nathaniel Hansen, Melissa Martinez, Ritin Sharma, Christopher Hulme, Travis Dunckley, Patrick Pirotte, Ramon Velazquez

TARGETING AΒ PRODUCTION WITH A CELL PENETRATING CIS-Γ-AMINO-L-PROLINE DERIVED PEPTIDE: EVIDENCE FROM IN VITRO STUDIES AND APP/PS1 MICE

Dayaneth Jácome, Marina Pérez-Palau, Inés Martínez-Soria, Laia Lidón, Cristina Vergara, Daniel Carbajo, Ximena Pulido, Fernando Albericio, Miriam Royo, Rosalina Gavín, José Antonio Del Río

DEVELOPMENT OF TOOLS TO MODULATE ADAM10 TRAFFICKING IN ALZHEIMER’S DISEASE

Jasmine Molaschi, Annarita D'Urso, Lorenzo Targa, Silvia Pelucchi, Ramona Stringhi, Giovanni Di Muccio, Alice Romagnoli, Anna La Teana, Francesca Vasile, Laura Belvisi, Monica Di Luca, Elena Marcello

Cookies

We use essential cookies to run the site. Analytics cookies are optional and help us improve World Wide. Learn more.